Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)

NCT00498797 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00498797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00498797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-blind, Placebo-controlled, Randomised Study to Assess the Efficacy and Safety of Docetaxel (Taxotere)/Prednisolone/ZD6474 vs Docetaxel/Prednisolone/Placebo in Patients With Hormone Refractory Prostrate Cancer (HRPC)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2005
Completion date
September 30, 2008
Enrollment
86 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hormone refractory, metastatic, prostate cancer